Parenteral anticoagulation in ambulatory patients with cancer-Reference-Cited by-同舟云学术

Parenteral anticoagulation in ambulatory patients with cancer

Published:2017-09-11 Issue:1 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Akl Elie A¹,Kahale Lara A²,Hakoum Maram B³,Matar Charbel F¹,Sperati Francesca⁴,Barba Maddalena⁵,Yosuico Victor ED⁶,Terrenato Irene⁷,Synnot Anneliese⁸⁹,Schünemann Holger¹⁰

Affiliation:

1. Department of Internal Medicine; American University of Beirut Medical Center; Beirut Lebanon

2. Faculty of Medicine; American University of Beirut; Beirut Lebanon

3. Family Medicine; American University of Beirut; Beirut Lebanon

4. Biostatistics-Scientific Direction; Regina Elena National Cancer Institute; Rome Italy

5. Division of Medical Oncology 2 - Scientific Direction; IRCCS Regina Elena National Cancer Institute; Rome Italy

6. Buffalo Medical Group; Buffalo New York USA

7. Biostatistics-Scientific Direction; IRCCS Regina Elena National Cancer Institute; Rome Italy

8. Cochrane Australia, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia

9. Cochrane Consumers and Communication, Centre for Health Communication and Participation, School of Psychology and Public Health; La Trobe University; Bundoora Australia

10. Departments of Health Research Methods, Evidence, and Impact and of Medicine; McMaster University; Hamilton Canada

Publisher

Wiley

Subject

Pharmacology (medical)

Reference252 articles.

1. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study;Agnelli;Lancet Oncology,2009

2. A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study;Agnelli;Blood,2008

3. Nadroparin for prevention of thromboembolic events in cancer patients receiving chemotherapy. a randomized placebo-controlled double-blind study;Agnelli;Support Care Cancer,2009

4. Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer;Barni;Support Care Cancer,2011

5. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study;Barni;Journal of Translational Medicine,2011

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 局所進行外耳道扁平上皮癌の化学放射線療法中にS状静脈洞血栓症を発症した1例;Practica Oto-Rhino-Laryngologica;2024

2. Impact of early heparin therapy on outcomes in patients with solid malignancy associated sepsis: a marginal structural model causal analyse;Frontiers in Pharmacology;2023-12-04

3. High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients;Anticancer Research;2023-06-23

4. Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases;Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice;2023-03-01

5. Pediatric cancer‐associated thrombosis: Analysis from a tertiary care cancer center in India;Pediatric Blood & Cancer;2022-11-19